Healthcomms Consulting has an excellent track record in delivering campaigns, corporate programmes and specialist market access projects.
Hernia repair is one of the most common procedures performed by the NHS. 80,000 inguinal hernia operations are performed on the NHS each year. Hernias can be painful and debilitating for people living with them.
There are around 367,000 cases of cancer every year. Cancer treatment continues to advance with new treatments and therapies regularly becoming available. The Cancer Drugs Fund was launched in 2011 to give patients access to innovative cancer drugs that might not otherwise be available on the NHS.
Increasing patient demand and slower growth in budgets has required the NHS to make tough decisions on the treatment options available to individual patients. Over time this has led to huge regional disparities as local commissioners have set their own criteria for patient eligibility for treatment.
The All-Party Parliamentary Group on Obesity calls for Government action to solve the ongoing obesity crisis in the UK, through prioritisation of prevention and treatment for people living with obesity.
Healthcomms UK worked with Insightec to change a draft research only recommendation from NICE regarding guidance of Unilateral MRI-guided focused ultrasound (MRgFUS) thalamotomy for treatment-resistant essential tremor.
Healthcomms Consulting worked with Ottobock to ensure that NHS England gave patients access to life changing microprocessor knees technology through the specialised commissioning process. Following the campaign, NHS England now have a commissioning policy that gives widespread access to microprocessor knees.
Healthcomms Consulting led a campaign with the UK Sepsis Trust to place sepsis at the top of the Government’s priority list. This culminated in an announcement from Jeremy Hunt stating that sepsis was a national priority and he would launch a commissioning lever.
Ruptured AAAs are known to kill around 5,000 people every year in the UK. To prevent an aneurysm rupturing, the existing guidance had stated that a treatment option known as EVAR should be available to all patients.
